If you are a diabetes patient who has taken Actos, ActoPlus Met, ActoPlus Met XR or Duetact and were diagnosed with bladder cancer, you may be entitled to compensation.
According to the FDA safety announcement concerning Actos and bladder cancer, patients taking pioglitazone, an ingredient in the drug, for more than a year may have an increased risk of developing cancerous tumors in the bladder. The drug maker, Takeda Pharmaceutical withheld information about the risk of cancer associated with Actos, and failed to provide adequate warnings about the diabetes drug.
Actos (pioglitazone), also ActoPlus Met, ActoPlus Met XR and Duetact
Manufacturer: Takeda Pharmaceutical
In light of the link between Actos and bladder cancer, the FDA has advised that pioglitazone should not be prescribed to people who have bladder cancer and should be used with caution in patients with a history of the disease. The agency also advised users to be on alert for side effects, such as:
Due to the possible Actos bladder cancer link, the agency also announced that the risk will be reflected in the drug’s label and patient medication guide.
If you or someone you love has taken Actos and experienced any of the symptoms above, contact your doctor immediately. After speaking with your physician, contact us for your risk-free consultation for an Actos lawsuit. With over 65 years of experience in St. Louis, Goldblatt Singer is the best choice for your Actos case.
To protect you from COVID-19, we are offering a quick & easy remote intake process. LEARN MORE HERE